1. Home
  2. NXTC vs WWR Comparison

NXTC vs WWR Comparison

Compare NXTC & WWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXTC
  • WWR
  • Stock Information
  • Founded
  • NXTC 2015
  • WWR 1977
  • Country
  • NXTC United States
  • WWR United States
  • Employees
  • NXTC N/A
  • WWR N/A
  • Industry
  • NXTC Biotechnology: Pharmaceutical Preparations
  • WWR Metal Mining
  • Sector
  • NXTC Health Care
  • WWR Basic Materials
  • Exchange
  • NXTC Nasdaq
  • WWR Nasdaq
  • Market Cap
  • NXTC 31.6M
  • WWR 36.9M
  • IPO Year
  • NXTC 2019
  • WWR N/A
  • Fundamental
  • Price
  • NXTC $0.89
  • WWR $0.53
  • Analyst Decision
  • NXTC Strong Buy
  • WWR
  • Analyst Count
  • NXTC 2
  • WWR 0
  • Target Price
  • NXTC $4.00
  • WWR N/A
  • AVG Volume (30 Days)
  • NXTC 218.5K
  • WWR 381.5K
  • Earning Date
  • NXTC 11-07-2024
  • WWR 11-15-2024
  • Dividend Yield
  • NXTC N/A
  • WWR N/A
  • EPS Growth
  • NXTC N/A
  • WWR N/A
  • EPS
  • NXTC N/A
  • WWR N/A
  • Revenue
  • NXTC N/A
  • WWR N/A
  • Revenue This Year
  • NXTC N/A
  • WWR N/A
  • Revenue Next Year
  • NXTC N/A
  • WWR N/A
  • P/E Ratio
  • NXTC N/A
  • WWR N/A
  • Revenue Growth
  • NXTC N/A
  • WWR N/A
  • 52 Week Low
  • NXTC $0.87
  • WWR $0.40
  • 52 Week High
  • NXTC $2.57
  • WWR $0.70
  • Technical
  • Relative Strength Index (RSI)
  • NXTC 22.88
  • WWR 43.30
  • Support Level
  • NXTC $1.06
  • WWR $0.57
  • Resistance Level
  • NXTC $1.21
  • WWR $0.58
  • Average True Range (ATR)
  • NXTC 0.10
  • WWR 0.03
  • MACD
  • NXTC -0.02
  • WWR -0.01
  • Stochastic Oscillator
  • NXTC 5.21
  • WWR 2.50

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.

About WWR Westwater Resources Inc.

Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.

Share on Social Networks: